Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1330–1334. doi: 10.1038/bjc.1995.258

Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma.

M Brada 1, G Thomas 1, S Elyan 1, N James 1, F Hines 1, S Ashley 1, H Marsh 1, B A Bell 1, S Stenning 1
PMCID: PMC2033859  PMID: 7779733

Abstract

Radiotherapy, although clearly beneficial in patients with high-grade glioma, is largely palliative, and a protracted course of treatment may not be the most appropriate approach in the context of limited survival. We therefore assessed the feasibility, toxicity and survival results of a short accelerated radiotherapy regimen given twice daily over a period of 3 weeks. A total of 116 patients with high-grade glioma were treated with radiotherapy in a prospective study using an accelerated fractionation regimen. The total dose of 55 Gy was given in 32-36 fractions of 1.72-1.53 Gy, twice daily 5 days a week, with a minimum 6 h interval between fractions. Toxicity was assessed using Karnofsky performance status scale and in the later part of the study with the Barthel index. Survival data were compared with a control group treated with 60 Gy in 30 daily fractions in a previous MRC study, matched for known prognostic factors. The median survival of 116 patients treated with accelerated radiotherapy was 10 months. Survival comparison of accelerated patients with matched controls treated with conventional fractionation demonstrated a hazard ratio of 1.13 (95% confidence interval 0.85-1.51; P = 0.39). Early treatment toxicity was acceptable, with only seven patients developing transient decrease in performance status. The accelerated radiotherapy regimen was logistically feasible and acceptable to patients, carers and staff. Treatment time was reduced without apparent increase in early toxicity and there was no loss of survival benefit. The effectiveness and convenience of a short accelerated regimen makes this a suitable alternative to a 6 week course of radiotherapy in patients with high-grade glioma. However, a full randomised trial comparing conventional and accelerated radiotherapy may be required as proof of equivalence.

Full text

PDF
1330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ang K. K., Jiang G. L., Guttenberger R., Thames H. D., Stephens L. C., Smith C. D., Feng Y. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol. 1992 Dec;25(4):287–294. doi: 10.1016/0167-8140(92)90249-t. [DOI] [PubMed] [Google Scholar]
  2. Bleehen N. M., Stenning S. P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991 Oct;64(4):769–774. doi: 10.1038/bjc.1991.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang C. H., Horton J., Schoenfeld D., Salazer O., Perez-Tamayo R., Kramer S., Weinstein A., Nelson J. S., Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983 Sep 15;52(6):997–1007. doi: 10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  4. Curran W. J., Jr, Scott C. B., Nelson J. S., Weinstein A. S., Phillips T. L., Murray K., Fischbach A. J., Yakar D., Schwade J. G., Powlis W. D. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer. 1992 Dec 15;70(12):2909–2917. doi: 10.1002/1097-0142(19921215)70:12<2909::aid-cncr2820701230>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  5. Dische S., Warburton M. F., Saunders M. I. Radiation myelitis and survival in the radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):75–81. doi: 10.1016/0360-3016(88)90349-5. [DOI] [PubMed] [Google Scholar]
  6. Douglas B. G., Worth A. J. Superfractionation in glioblastoma multiforme--results of a phase II study. Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1787–1794. doi: 10.1016/0360-3016(82)90303-0. [DOI] [PubMed] [Google Scholar]
  7. Fulton D. S., Urtasun R. C., Shin K. H., Geggie P. H., Thomas H., Muller P. J., Moody J., Tanasichuk H., Mielke B., Johnson E. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1709–1712. doi: 10.1016/0360-3016(84)90533-9. [DOI] [PubMed] [Google Scholar]
  8. Goffman T. E., Dachowski L. J., Bobo H., Oldfield E. H., Steinberg S. M., Cook J., Mitchell J. B., Katz D., Smith R., Glatstein E. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol. 1992 Feb;10(2):264–268. doi: 10.1200/JCO.1992.10.2.264. [DOI] [PubMed] [Google Scholar]
  9. Hernandez J. C., Maruyama Y., Yaes R., Chin H. W. Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors. J Neurooncol. 1990 Aug;9(1):41–45. doi: 10.1007/BF00167067. [DOI] [PubMed] [Google Scholar]
  10. Keim H., Potthoff P. C., Schmidt K., Schiebusch M., Neiss A., Trott K. R. Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiother Oncol. 1987 May;9(1):21–26. doi: 10.1016/s0167-8140(87)80215-3. [DOI] [PubMed] [Google Scholar]
  11. Ludgate C. M., Douglas B. G., Dixon P. F., Steinbok P., Jackson S. M., Goodman G. B. Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys. 1988 Nov;15(5):1091–1095. doi: 10.1016/0360-3016(88)90189-7. [DOI] [PubMed] [Google Scholar]
  12. Nelson D. F., Curran W. J., Jr, Scott C., Nelson J. S., Weinstein A. S., Ahmad K., Constine L. S., Murray K., Powlis W. D., Mohiuddin M. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193–207. doi: 10.1016/0360-3016(93)90340-2. [DOI] [PubMed] [Google Scholar]
  13. Payne D. G., Simpson W. J., Keen C., Platts M. E. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer. 1982 Dec 1;50(11):2301–2306. doi: 10.1002/1097-0142(19821201)50:11<2301::aid-cncr2820501114>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shin K. H., Muller P. J., Geggie P. H. Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer. 1983 Dec 1;52(11):2040–2043. doi: 10.1002/1097-0142(19831201)52:11<2040::aid-cncr2820521112>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES